Skip to main content

Table 1 Baseline characteristics, hepatitic outcomes and thyrotropin outcome profiles in all 18 thyroiditis patients.

From: The natural history of interferon-α induced thyroiditis in chronic hepatitis c patients: a long term study

Subject

No.

Gender

Age

Hepatitis C Genotype

Duration of Therapy (weeks)

SVR

End of Rx TSH

TSH at 12 months

TSH at 24 months

TSH at 36 months

1

M

26

1a

48

Y

2.1

1.8

2.8

3.4

2

M

51

2

24

Y

1.7

3.2

3.1

2.7

3

M

54

3

24

Y

3.8

2.3

2.2

3.2

4

M

49

4

48

Y

1.1

1.4

2.1

2.3

5*

F

42

2

24

Y

1.6

1.8

2.1

1.9

6*

F

34

3

24

Y

2.4

2.7

2.1

2.0

7

F

49

4

48

Y

3.1

2.9

2.7

2.2

8*

F

49

1

48

Y

0.03

1.5

1.2

1.3

9

F

50

2

24

Y

2.2

2.1

2.4

2.5

10*

F

37

4

48

Y

6.5

4.5

5.2

2.3

11

F

43

4

48

Y

1.8

1.9

2.3

2.1

12

F

42

3

24

Y

2.1

2.3

1.7

2.5

13*

F

43

1

48

N

10.5

2.3

1.8

2.4

14*

F

51

3

24

Y

8.8

4.0

3.8

2.3

15

M

57

1

48

N

2.2

2.7

1.9

1.2

16

F

38

3

24

Y

1.9

2.2

2.3

3.7

17

M

57

1

48

Y

4.5

2.5

3.6

2.8

18

F

37

3

24

Y

3.4

3.3

2.5

2.8

  1. *; Cases 5 and 6 required short-term thyroxine supplement, case 8 progressed to develop post-interferon Graves' like thyrotoxicosis, cases 10 and 14 had subclinical hypothyroidism and case 13 was in the hypothyroid phase at the end of treatment. SVR; Sustained virologic response, Rx; Treatment, TSH; Thyrotropin.